Abstract
Metastatic melanoma has intrinsic resistance as a central problem to be refractory to almost therapeutic interventions. Despite numerous attempts to treat melanoma, e.g. chemo-, radio- and immunotherapy, the patients survival rate remains with poor prognosis. RAF-type proteins are intermediates in the MAPK and RAS signaling pathways cascade and affect cell proliferation. Mutations in BRAF…